Susquehanna Financial Group LLLP recently announced the acquisition of new stake in Atossa Therapeutics Inc. (NASDAQ:ATOS). This fresh investment now brings its stake to 0.78% valued currently at $0.27 million. In addition, Tower Research Capital LLC raised its holdings by 1676.0 to 1676.0 shares.
With over 1.07 million Atossa Therapeutics Inc. (ATOS) shares trading Tuesday and a closing price of $2.51 on the day, the dollar volume was approximately $2.69 million. The shares have shown a negative weekly performance of -18.77% and its price on 09/01/20 lost nearly -1.57%. Currently, there are 10.40M common shares owned by the public and among those 10.37M shares have been available to trade.
An analysis of what Wall Street brokers have to say about the expected price targets for this stock gives us this picture: 1 analysts who have offered their price forecasts for ATOS have a consensus price objective of $8.00. The analysts have set the share’s price value over the next 12 months at a high of $8.00 and a low of $8.00 should the stock experience a downside. Incidentally, analysts’ outlook for the Atossa Therapeutics Inc. stock is 2.00 for the next 12 months. But an upside of 68.63% will see the stock hit the forecast high price target while mean target price for the stock is $8.00.
Insiders at the company have transacted a total of 0 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 0 of these insider trades were purchases, accounting for 0 shares. Insider sales of the common stock occurred on 0 occasions, with total insider shares sold totaling 0 shares.
The top 3 mutual fund holders in Atossa Therapeutics Inc. are Vanguard Extended Market Index Fu, Fidelity Extended Market Index Fu, and Fidelity Total Market Index Fund. Vanguard Extended Market Index Fu owns 0.12 million shares of the company’s stock, all valued at over $0.46 million. Fidelity Total Market Index Fund now owns shares totaling to 0.27% of the shares outstanding.
Shares of Atossa Therapeutics Inc. (NASDAQ: ATOS) opened at $2.54, down -$0.01 from a prior closing price of $2.55. However, the script later closed the day at $2.51, down -1.57%. The company’s stock has a 5-day price change of -18.77% and -8.06% over the past three months. ATOS shares are trading 59.87% year to date (YTD), with the 12-month market performance up to 27.41% higher. It has a 12-month low price of $0.75 and touched a high of $5.08 over the same period. Currently, 1.07 million shares have been traded, compared to an average intraday trading volume of 833.43K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -26.83%, -31.73%, and 15.89% respectively.
Institutional ownership of Atossa Therapeutics Inc. (NASDAQ: ATOS) shares accounts for 2.90% of the company’s 10.40M shares outstanding. Mutual fund holders own 0.88%, while other institutional holders and individual stakeholders account for 2.36% and 0.04% respectively.
It has a market capitalization of $25.78M and a beta (3y monthly) value of 2.32. The earnings-per-share (ttm) stands at -$1.39. Price movements for the stock have been influenced by the stock’s volatility, which stands at 12.04% over the week and 8.12% over the month.
Analysts forecast that Atossa Therapeutics Inc. (ATOS) will achieve an EPS of -$0.32 for the current quarter, -$0.35 for the next quarter and -$0.84 for 2021. The lowest estimate earnings-per-share for the quarter is -$0.32 while analysts give the company a high EPS estimate of -$0.32. Comparatively, EPS for the current quarter was -$0.36 a year ago. Earnings per share for the fiscal year are expected to increase by 63.10%, and 34.40% over the next financial year.
If you are looking to buy this stock, then you may note that the average analyst recommendation by 1 brokerage firm advisors rate Atossa Therapeutics Inc. (ATOS) as a “Moderate Buy” at a consensus score of 2.00. Specifically, 1 Wall Street analysts polled rate the stock as a buy, while 0 of the 1 advise that investors “hold,” and 0 rated it as a “Sell.”
Looking at the support for the ATOS, a number of firms have released research notes about the stock. Maxim Group stated their Buy rating for the stock in a research note on January 26, 2018, with the firm’s price target at $2.